Pathogenicity of POFUT1 Mutations in Two Chinese Families with Dowling‐Degos Disease

Chaoran Li,Yang Brooks,Weixue Jia,Daguang Wang,Xiuli Xiao,Q. Li,Zhirong Yao,Quanzong Mao,B. Wang

DOI: https://doi.org/10.1111/jdv.13323

2015-01-01

Abstract:mary screening, an option which we clearly present in the 2014 guideline both in the text and in table 1 (option 3, ‘wise in case of suspicion of very early syphilis’). In the same way, the definition of early latent syphilis proposed by Drago et al. is already the official definition used throughout the world (and of course in the 2014 guideline). Having restated much of the guideline, Drago et al. go further and, based on still unpublished data and lack of other evidence base, propose that TT titres be used for the follow up of treated late latent syphilis. The authors of the 2014 guideline are firmly of the opinion that this is clearly lacking appropriate evidence and cannot be supported. TT titres have very poor correlation with disease activity and should be ignored in late latent syphilis when negative NTT is accepted as a demonstration of syphilis cure. Drago et al.’s comments regarding neurosyphilis can also not go unchallenged. Clinicians have known for over a century that early Treponema pallidum invasion of the nervous system can and does occur frequently. We agree that the ‘new atypical forms’ of neurosyphilis described since the 1970s are still seen but have remained extremely rare in patients appropriately treated with the recommended and simple regimens stated in the 2014 guideline. Furthermore, no syphilis treatment failure have been appropriately verified microbiologically, i.e. by demonstration of viable T. pallidum and exclusion of reinfection, after treatment with recommended first-line regimen stated in the 2014 guideline. Serological failures (whose definition is arbitrary) are not clinical failures which remain the exception (when they are not disputable) and must be balanced with the availibility, cost and risk of premature interruption of therapeutic schemes such as the one proposed by Drago et al. (based again on unpublished data). We certainly prefer optimal regimens to sub-optimal ones, but the arguments given by Drago et al. are too weak. On the basis of available evidence, benzathine penicillin G (BPG), remains the best treponemicidal drug and we will await well-designed comparative randomised controlled clinical trials with adequate follow-up before we ammend any recommendation to challenge its place. BPG therapy guarantees 100% compliance, is easy to administer, and is relatively cheap across most of Europe.